Celcuity's breast cancer win; Odyssey plans $205M IPO

Celcuity’s breast cancer drug wins again; Odyssey charts $205M IPO; Gene therapy biotech gets $43M; Mirum scores Phase 2b win for liver drug; MacroGenics expands royalty deal; Indivior begins $175M share repurchase Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals…

ENDPOINTS · 2026-05-04

Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...

Source: Endpoints News